Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how oncology practices can work better with payers to increase biosimilar adoption and how those collaborations can be applied to other disease areas, such as immunology and neurology.
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, commented on how oncology practices can leverage their experience with oncology biosimilars and work with payers to increase biosimilar accessibility and improve adoption rates.
Transcript
Although oncology biosimilars have experienced pretty good adoption rates overall, a recent study found that biosimilars for cancer are significantly more likely to have coverage restrictions than their reference products. How can oncology practices work better with payers to ensure adequate coverage for biosimilars and better market competition?
I did see that study. And I think you're right. We would have thought as biosimilar utilization continues to grow [that] some of our managed care and payer policies would also reflect that. But I think you're also overcoming historical agreements in terms of rebating and some of the contracting but also some of the real-world evidence that might be in favor of the reference products.
But what we need to do, and continue to do, is engage our key opinion leaders. And when we're meeting with payers and providers, we're explaining the data—at least creating parity access between biosimilar reference product. So if we are looking to reduce costs for a plan or reduce total health care utilization, that's really going to be a positive thing. And when we came out of the Oncology Care Model, we saw one of the drivers and the key success of that model was the adoption of biosimilars.
So now, how do we leverage that for the provider group and the payer group, ensure at least parity or prioritization, and start to have more of those transparent conversations as we move forward? I think it's gonna be a really good thing but I also recognize those dynamics from our managed care partners that we also have to navigate from a cost perspective and rebate perspective.
How can this collaboration be translated to other health care fields, such as multiple sclerosis and ophthalmology?
I think it is relatable. And I think what we've done in oncology is great, but I think we can bring that into more of the inflammatory disease states, with adalimumab, and I think we can bring it into multiple sclerosis and brain health, with those biosimilars and that disruption that's about to occur there. And I think having more options and having a less costly option that still provides that same therapeutic benefit, I think is a good thing.
EC Approves First MS Biosimilar; Coherus Receives CRL for Neulasta Onpro Competitor
September 27th 2023With the European Commission's (EC) approval of Tyruko, Europe receives its first natalizumab biosimilar and first biosimilar to treat multiple sclerosis (MS), while Coherus Biosciences received a complete response letter (CRL) for its biosimilar for Neulasta Onpro.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
How Streamlining Development Can Save the US Biosimilar Industry
August 20th 2023On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, expanded on ways to make biosimilar development faster and cheaper without compromising on safety and efficacy and how these practices can ensure a sustainable market for the future.
Despite Global Increase in Amjevita Sales, US Sales Dropped 63%
August 5th 2023Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.
Abstracts Highlight Growing Comfortability With Trastuzumab Biosimilars in Breast Cancer
July 31st 2023Abstracts presented at the annual meeting of the American Society of Clinical Oncology (ASCO 2023) emphasized the safety and efficacy of a trastuzumab biosimilar in treating HER2-positive breast cancer and growing utilization of trastuzumab biosimilars over time.
2 Clarke Drive
Cranbury, NJ 08512